Results of the final phase of the Oxford Vaccine trial

According to the results of the final phase of the Oxford Vaccine trial, only three out of about 24,000 people saw the side effects of the vaccine. If the results were published in the medical journal Lancet, none of the people who were given the vaccine died, nor were they admitted to the hospital.

Research published in the Lancet stated that during the test, the corona vaccine was found to have 62% effective capacity when given two full doses, and about 90% effective at first half dose and then full dose. Now the pharmaceutical company AstraZeneca has expressed hope that the Corona vaccine will be approved by the regulatory body in the coming week.
23,745 people took part in the UK, Brazil and South Africa, according to Oxford trial data. Of these, 82 percent were aged between 18 and 55 years. Later people aged 56 years or more were made part of this trial.

Research published in The Lancet states that the Oxford vaccine has been found to be completely safe. During the trial, serious side effects were seen in three out of about 24,000 people, possibly linked to the vaccine. Research said that these three people have either recovered now or are on the verge of recovery. According to a media report, the lower dose of the Oxford vaccine has worked much better than the full dose.

Results of the final phase of the Oxford Vaccine trial
Results of the final phase of the Oxford Vaccine trial

The Lancet’s latest research is considered good news for India. This is because the Serum Institute has entered into a deal with AstraZeneca to make 100 million doses of the vaccine. In India, this vaccine is expected to be approved by January. At the same time, the central government is considering giving vaccines to 300 million people by July.